An NRP1/MDM2‐Targeted D‐Peptide Supramolecular Nanomedicine for High‐Efficacy and Low‐Toxic Liver Cancer Therapy

Yunjiang Zhou,Yaxin Chen,Yingying Tan,Rong Hu,Miao‐Miao Niu

DOI: https://doi.org/10.1002/adhm.202002197

IF: 10

2021-03-09

Advanced Healthcare Materials

Abstract:<p>Supramolecular nanomedicines based on self‐assembly of D‐peptides have been of great interest as potential candidates for cancer therapy. Neuropilin‐1 (NRP1) and mouse double minute 2 (MDM2) have been considered as the anticancer targets because of their overexpression in cancers. However, NRP1/MDM2‐targeted D‐peptide supramolecular nanomedicines remain unreported. Here, a potent anticancer D‐peptide supramolecular nanomedicine targeting NRP1 and MDM2, termed as NMTP‐5, is identified by using structure‐based virtual screening techniques. NMTP‐5 exhibits good biostability and strong cellular uptake performance. Moreover, NMTP‐5 displays strong anticancer activity to SK‐Hep‐1 cells in vitro and in vivo, with no apparent host toxicity. This work demonstrates that NMTP‐5 can be used as a potential chemotherapeutic agent for the treatment of liver cancer.</p>

nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials

What problem does this paper attempt to address?

The main aim of this paper is to develop a D-amino acid peptide-based supramolecular nanomedicine targeting Neuropilin-1 (NRP1) and Mouse Double Minute 2 (MDM2) (named NMTP-5) for efficient and low-toxicity treatment of liver cancer.

The research background is that hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths worldwide, and chemotherapy, as a primary adjuvant therapy, is often limited by severe side effects and drug resistance. D-amino acid peptide nanomedicines have garnered increasing attention due to their superior properties, such as low toxicity, good biocompatibility, and high specificity and affinity for biological molecular targets. However, D-amino acid peptides typically have difficulty penetrating cell membranes, limiting their effectiveness on intracellular targets. Therefore, developing novel D-amino acid peptide nanomedicines with good cellular uptake performance is crucial for cancer treatment.

NRP1, as a transmembrane glycoprotein, is overexpressed in various cancers and is closely related to the regulation of tumor angiogenesis, metastasis, and vascular permeability. MDM2 is a negative regulator of p53, inhibiting p53-mediated cell cycle arrest and apoptosis by binding to and promoting the degradation of p53. Since MDM2 is overexpressed in many cancers, including liver cancer, disrupting the MDM2-p53 interaction is considered a promising strategy for cancer treatment.

The research team successfully identified NMTP-5 using structure-based virtual screening technology. This D-amino acid peptide supramolecular nanomedicine exhibits good biological stability, strong cellular uptake performance, and potent anticancer activity against SK-Hep-1 cells both in vitro and in vivo, with no significant host toxicity. The research results indicate that NMTP-5 can enter cells by binding to NRP1 and then induce cell death by targeting MDM2 to activate the p53 signaling pathway, showing potential as a chemotherapeutic agent for liver cancer.